EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer

Chen Qian iD, Qian Yang, Mirja Rotinen, Rongrong Huang, Hyoyoung Kim, Brad Gallent, Yiwu Yan, Radu M Cadaneanu, Baohui Zhang, Salma Kaochar, Stephen J Freedland, Edwin M Posadas und 14 weitere

Nucleic Acids Research · 22.07.2024 · 52 (13) · 7740-7760

DOI: 10.1093/nar/gkae547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 27.06.2024. Verfasst von Chen Qian und 25 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Urology and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Hauptthemen laut MEDLINE: Receptors, Androgen, Adenocarcinoma, Receptors, Glucocorticoid, Prostatic Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Institute for Prostate Cancer Research, UCLA Prostate Cancer SPORE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demonstrate that ONECUT2 (OC2) activates resistance through multiple drivers associated with adenocarcinoma, stem-like and neuroendocrine (NE) variants. Direct OC2 gene targets include the glucocorticoid receptor (GR; NR3C1) and the NE splicing factor SRRM4, which are key drivers of lineage plasticity. Thus, OC2, despite its previously described NEPC driver function, can indirectly activate a portion of the AR cistrome through epigenetic activation of GR. Mechanisms by which OC2 regulates gene expression include promoter binding, enhancement of genome-wide chromatin accessibility, and super-enhancer reprogramming. Pharmacologic inhibition of OC2 suppresses lineage plasticity reprogramming induced by the AR signaling inhibitor enzalutamide. These results demonstrate that OC2 activation promotes a range of drug resistance mechanisms associated with treatment-emergent lineage variation in PC and support enhanced efforts to therapeutically target OC2 as a means of suppressing treatment-resistant disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenAdenocarcinomaReceptors, GlucocorticoidProstatic NeoplasmsDrug Resistance, NeoplasmBenzamidesNitrilesGene Expression Regulation, NeoplasticMaleHumansCell Line, TumorPhenylthiohydantoinNerve Tissue ProteinsEpigenesis, GeneticRNA-Binding ProteinsNeuroendocrine TumorsAnimalsCell LineageMice

Substanzen

Receptors, AndrogenReceptors, GlucocorticoidenzalutamideBenzamidesNR3C1 protein, humanNitrilesSRRM4 protein, humanPhenylthiohydantoinAR protein, humanNerve Tissue Proteins

Autor:innen und Institutionen

  • Departments of Urology and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Departments of Urology and Computational Biomedicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Department of Health Sciences, Public University of Navarre, Pamplona, Navarra, Spain.
  • Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA.
  • Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Department of Surgical and Perioperative Care, VA Greater Los Angeles; Department of Urology and Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, UCLA, Box 951738, 10833 Le Conte Ave 66-188 CHS…

ORCID-Profile: Chen Qian, Moray J Campbell

Förderung

  • NCI NIH HHS
  • Institute for Prostate Cancer Research
  • UCLA Prostate Cancer SPORE
  • Department of Defense

Zitieren

APA

Qian, C., Yang, Q., Rotinen, M., Huang, R., Kim, H., Gallent, B., Yan, Y., Cadaneanu, R. M., Zhang, B., Kaochar, S., Freedland, S. J., Posadas, E. M., Ellis, L., Di Vizio, D., Morrissey, C., Nelson, P. S., Brady, L., Murali, R., Campbell, M. J., …, & Freeman, M. R. (2024). ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Research, 52(13), 7740-7760. https://doi.org/10.1093/nar/gkae547

Vancouver

Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, et al. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Research. 2024;52(13):7740-7760. doi:10.1093/nar/gkae547

BibTeX
@article{Qian2024,
  author = {Qian, Chen and Yang, Qian and Rotinen, Mirja and Huang, Rongrong and Kim, Hyoyoung and Gallent, Brad and Yan, Yiwu and Cadaneanu, Radu M and Zhang, Baohui and Kaochar, Salma and Freedland, Stephen J and Posadas, Edwin M and Ellis, Leigh and Di Vizio, Dolores and Morrissey, Colm and Nelson, Peter S and Brady, Lauren and Murali, Ramachandran and Campbell, Moray J and Yang, Wei and Knudsen, Beatrice S and Mostaghel, Elahe A and Ye, Huihui and Garraway, Isla P and You, Sungyong and Freeman, Michael R},
  title = {ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer},
  journal = {Nucleic Acids Research},
  year = {2024},
  volume = {52},
  number = {13},
  pages = {7740--7760},
  doi = {10.1093/nar/gkae547}
}
Kostenlos starten →